Á lódáil...
Expanding role of lenalidomide in hematologic malignancies
Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia...
Na minha lista:
| Foilsithe in: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Dove Medical Press
2015
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4427066/ https://ncbi.nlm.nih.gov/pubmed/25999761 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S81310 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|